(1 - 13 from 19
)
Google News: Braly's departure occurred sooner than many expected
[Indianapolis Business Journal] - Erik Gordon, a University of Michigan business professor who follows the health-care industry, predicted in mid-August that Braly had "bought herself some time because it would be unusual to remove a CEO in the middle of a major acquisition." But with
WellPoint's CEO Braly Resigns Amid Shareholder Criticism
www.bloomberg.com
[Bloomberg] - “They need a CEO who has demonstrated by his or her experience that they have the expertise to run a company the size that WellPoint will be, and they need them sooner rather than later,” said Erik Gordon, a professor at the University of Michigan's
Different development paths for BMS, Lilly intersect with failures
www.fiercepharma.com
[FiercePharma] - They still can fail," University of Michigan professor Erik Gordon tells Bloomberg. - here's the Eli Lilly press release - see the Bloomberg story - get more from Bloomberg Related Articles: Lilly's Alzheimer's drug solanezumab flunks out, but CEO sees
WellPoint Investor Royal Capital Calls for CEO Ouster
www.bloomberg.com
[Bloomberg] - That may mean Braly is safe at least until the end of the year, when the acquisition is expected to close, said Erik Gordon, a University of Michigan business professor who follows the health industry. While the board has backed Braly, “in the investor
sorted by relevance / date